Development and Manufacturing Agreement Partnership for Development of Anti-HIV and Anti-SARS-CoV-2 Therapies
Samsung Biologics and Enzolytics announced the signing of a strategic CDMO partnership agreement for the development and manufacturing of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.
College Station/USA; Incheon/South Korea — Under the terms of an agreement between Samsung Biologics and Enzolytics, the South Korean company will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics.
The Enzolytics protocol offers the opportunity to implement AI analysis and provides a platform for creating multiple fully human Monoclonal Antibodies targeting conserved immutable sites on the virus and offering a cure for these viruses. A stable cell line will be manufactured with support from Samsung Biologics' R&D Center in San Francisco. Its related clinical trial materials will be manufactured at Samsung Biologics headquarters in Incheon, South Korea.